ALPS Advisors’s Sarepta Therapeutics SRPT Stock Holding History

ALPS Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.55M	Buy	139,944 +33,395	+31%	+$625K	0.01%	461
2026 Q2	$1.91M	Buy	106,549 +21,080	+25%	+$399K	0.01%	537
2026 Q1	$1.86M	Sell	85,469 -568	-0.7%	-$11K	0.01%	420
2025 Q4	$1.85M	Buy	+86,037	New	+$1.81M	0.01%	406
2018 Q4	–	Sell	-1,554	Closed	-$251K	–	934
2018 Q3	$251K	Sell	1,554 -626	-29%	-$85.6K	﹤0.01%	906
2018 Q2	$288K	Sell	2,180 -84,505	-97%	-$7.97M	﹤0.01%	869
2018 Q1	$6.42M	Buy	86,685 +15,066	+21%	+$1M	0.05%	128
2017 Q4	$3.98M	Buy	+71,619	New	+$3.79M	0.03%	150

Other funds holding SRPT

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

ALPS Advisors's SRPT Position: Q3 2026 in Review

ALPS Advisors increased its Sarepta Therapeutics (SRPT) stake by 31% in Q3 2026, buying an estimated $625K and bringing the position to 139,944 shares worth $2.55M. The position accounts for 0.01% of the portfolio, ranked #461.

ALPS Advisors first reported a position in SRPT in Q4 2017 and has held it in 8 quarters since. The position peaked at $6.42M in Q1 2018. 104 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

ALPS Advisors held 139,944 shares of Sarepta Therapeutics worth $2.55M as of Q3 2026.
ALPS Advisors bought 33,395 Sarepta Therapeutics shares in Q3 2026, an estimated $625K.
Sarepta Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q3 2026, its #461 holding.
ALPS Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 8 quarters since.
ALPS Advisors's Sarepta Therapeutics position peaked at $6.42M in Q1 2018.
104 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.